JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bolanowski, P. J.
Right arrow Articles by Neville, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bolanowski, P. J.
Right arrow Articles by Neville, W. E.

The Journal of Thoracic and Cardiovascular Surgery, Vol 73, 221-224, Copyright © 1977 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Prostaglandin influence on pulmonary intravascular leukocytic aggregation during cardiopulmonary bypass

PJ Bolanowski, J Bauer, G Machiedo and WE Neville

A variety of pharmacologic agents have been infused during cardiopulmonary bypass in an attempt to prevent intravascular leukocytic aggregation in the lung. To date corticosteroids have been advocated because of their ability to stabilize lysosomes. We have studied two additional agents, prostaglandin E1 (PGE1) and dipyramidole (DIPYR) and compared their effects with those of methylprednisolone sodium succinate (MPSS) and a control group. The drugs were infused into the dog during perfusion and lung biopsies obtained before, during, and at the end of 2 hours of cardiopulmonary bypass using whole blood prime of the Bentley bubble oxygenator. The biopsies were interpreted by a pathologist who was unaware of the modality of treatment. Our results indicate that PGE1 provides more protection from intravascular pulmonary leukocytic aggregation than DIPYR and MPSS.


This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. J. Lodge, P. J. Chai, C. W. Daggett, R. M. Ungerleider, and J. Jaggers
METHYLPREDNISOLONE REDUCES THE INFLAMMATORY RESPONSE TO CARDIOPULMONARY BYPASS IN NEONATAL PIGLETS: TIMING OF DOSE IS IMPORTANT
J. Thorac. Cardiovasc. Surg., March 1, 1999; 117(3): 515 - 522.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
M. Ali, J. Becket, J. Brannan, J. Fleming, and K. Taylor
The effect of high dose aprotinin therapy on the systemic inflammatory response in a porcine model of cardiopulmonary bypass
Perfusion, May 1, 1996; 11(3): 278 - 280.
[PDF]

Home page
 PerfusionHome page
A. El-Gatit, A. Belboul, N. Al-Khaja, G. Radberg, A. El-Bishry, D. Roberts, and G. William-Olsson
Effects of Alprostadil (synthetic prostaglandin E1) on red and white cell filterability during cardiopulmonary bypass
Perfusion, January 1, 1992; 7(1): 21 - 26.
[Abstract] [PDF]

Home page
 PerfusionHome page
J. Massaut, N. Hennebert, F. Deuvaert, and J. Vanderrieviere
Changes in plasma leucocyte elastase levels during coronary surgery and effects of steroids and nifedipine infusion
Perfusion, October 1, 1991; 6(4): 253 - 259.
[Abstract] [PDF]

Home page
 PerfusionHome page
B. Glenville
Review article : Cardiac surgery using the patient's lungs as the oxygenator
Perfusion, July 1, 1987; 2(3): 161 - 166.
[PDF]

Home page
 PerfusionHome page
D. Jones, T. Higenbottam, D. Wheeldon, J. Kneeshaw, and D. Bethune
Prostacyclin, cardiopulmonary bypass and the alveolar capillary membrane
Perfusion, July 1, 1986; 1(3): 165 - 173.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1977 by The American Association for Thoracic Surgery.